MACE 3: As per the meta-analysis conducted by Sattar et al. [15], the comparisons among the treatment groups (placebo, semaglutide 1 mg, dulaglutide 1.5 mg, insulin degludec, insulin glargine) for the MACE-3 outcomes showed a hazard ratio (HR) of 0.83 (95% CI, 0.58-1.18) for Tirzepatide for MACE-3 (cardiovascular or undetermined cause, myocardial infarction (MI) and stroke); HR = 0.78 (95% CI, 0.56-1.08) for composite outcome of MACE-3 or HHF; HR = 0.67 (95% CI, 0.26-1.70) for HHF (hospitalized due to heart failure) and an HR = 0.80 (95% CI, 0.51-1.25) for all-cause death. The gene discussed is INS; the disease is heart failure.